Sarepta Therapeutics halted shipping its Duchenne muscular dystrophy gene therapy, Elevidys, for non-ambulatory patients after a second death due to acute liver failure. The company is working on enhanced safety regimens and plans discussions with the FDA. This development raises critical safety concerns in gene therapy for advanced-stage patients.